NCLEX Meds

Lisinopril - drug class

ACE Inhibitor (Antihypertensive)

Lisinopril - NC

Assess blood pressure, renal function, and potassium for early signs of complications. Lisinopril lowers blood pressure by blocking angiotensin II production.

Persistent cough warrants assessment. A dry, nagging cough may occur and often leads to discontinuation—inform patients to report this side effect.

Angioedema requires immediate action. Monitor for facial or airway swelling; this is a medical emergency, and the drug should be stopped right away.

Lisinopril - Critical Alerts

Black Box: Contraindicated in pregnancy. Lisinopril poses a significant risk of fetal injury or death; discontinue as soon as pregnancy is detected.

Losartan - Drug Class

ARB (antihypertensive)

Losartan - NC

Blood pressure control without the cough. Losartan is an angiotensin II receptor blocker that lowers blood pressure while avoiding the dry cough often associated with ACE inhibitors.

Monitor serum potassium and renal function. Potassium and kidneys require close watch due to the risk of hyperkalemia and potential kidney effects.

Instruct patients to rise slowly from sitting or lying positions. Postural changes demand patient caution to reduce the risk of dizziness and orthostatic hypotension.

Losartan - Critical Alerts

Black Box: Discontinue immediately if pregnancy is confirmed. Losartan is contraindicated during pregnancy due to the risk of fetal toxicity and developmental harm.

Metoprolol - Drug Class

Beta-1 Blocker (selective)

Metoprolol - NC

Hold for Low Apical Pulse. Check apical heart rate before administration; withhold if below 60 bpm.

May Mask Hypoglycemia Symptoms. Can conceal tachycardia in diabetic patients; monitor closely.

Use Cautiously in Asthma. Though β1-selective, high doses may affect β2 receptors and worsen bronchospasm.

Avoid Abrupt Discontinuation. Sudden withdrawal may cause rebound hypertension or angina.

Metoprolol - Critical Alerts

High Alert: Use with caution in heart failure. Though indicated in some cases, monitor for signs of worsening heart failure such as dyspnea, weight gain, or peripheral edema.

Amlodipine - Drug Class

CCB

Amlodipine - MoA

arterial vasodilation and decreased BP.

Metoprolol - NC

Edema is a common effect, not a fluid overload. Monitor for peripheral edema, particularly in the lower extremities, and differentiate from signs of heart failure.

Slow transitions reduce risk. Educate patients to rise slowly from bed or chairs to prevent dizziness from orthostatic hypotension.

Heart rate remains essentially unchanged. Unlike non-dihydropyridine agents, amlodipine typically does not significantly affect pulse rate, but monitor for hypotension.

Advise regular dental care and good oral hygiene. Gingival hyperplasia may occur with long-term use.

Metoprolol - Critical Alerts

Caution: Use with caution in patients with severe aortic stenosis. Amlodipine may worsen symptoms due to reduced preload tolerance in fixed-output cardiac conditions.

Diltiazem - Drug Class

CCB

Diltiazem - MoA

slowing AV node conduction and decreasing cardiac workload.

Diltiazem - NC

Monitor for bradycardia and conduction blocks. Regularly assess heart rate and rhythm; hold the dose and notify the physician if significant bradycardia or AV block is present.

Balance blood pressure and heart function. Monitor for hypotension and signs of worsening heart failure, especially in patients with reduced ejection fraction.

Titrate dosage based on cardiac response. IV administration requires continuous ECG monitoring; oral dosing may require gradual adjustment to maintain therapeutic effect.

Educate on postural safety and adherence. Instruct patients to rise slowly and not to abruptly stop the medication due to the risk of rebound hypertension or tachyarrhythmias.

Diltiazem - Critical Alerts

Caution: Use with caution in heart block or sick sinus syndrome. Diltiazem can worsen AV block or sinus node dysfunction, particularly without a functioning pacemaker.

Clonidine - Drug Class

Antihypertensive

Clonidine - MoA

Stimulates α2-adrenergic receptors in the brain, reducing sympathetic outflow; lowers peripheral vascular resistance and HR.

Clonidine - NC

Assess for sedation and dry mouth. Monitor for CNS depression, fatigue, and anticholinergic effects such as dry mouth, which are common but tolerable with continued use.

Monitor for orthostatic hypotension. Advise patients to change positions slowly and report dizziness or lightheadedness that may indicate a drop in blood pressure.

Evaluate renal function with long-term use. Since the kidneys partially excrete clonidine, renal labs should be monitored in patients with impaired function.

Support adherence to the dosing schedule. Emphasize the importance of taking clonidine at the same time daily and not missing doses due to the risk of rebound hypertension.

Clonidine - Critical Alerts

High Alert: Avoid abrupt discontinuation. Sudden withdrawal may result in severe rebound hypertensive crisis, agitation, and headache; taper the dose gradually under supervision.

Nitroprusside - Drug Class

vasodilator (antihypertensive emergency)

Nitroprusside - MoA

Releases nitric oxide to directly dilate arteries and veins, rapidly reducing BP and preload/afterload.

Nitroprusside - NC

Monitor blood pressure continuously. Because hypertension has an immediate onset and short half-life, arterial line monitoring is used in critical care settings to prevent excessive hypotension.

Assess for signs of cyanide toxicity. Prolonged or high-dose infusions may lead to cyanide or thiocyanate accumulation, especially in renal or hepatic impairment.

Protect from light during administration. Nitroprusside is light-sensitive and must be shielded to prevent degradation and loss of potency.

Titrate dose carefully based on response. Adjust infusion rates slowly and precisely to maintain safe hemodynamic control and prevent rebound effects

Nitroprusside - Critical Alerts

High Alert: Discontinue immediately if cyanide toxicity is suspected. Symptoms include altered mental status, metabolic acidosis, or cardiovascular instability; administer sodium thiosulfate as the antidote if indicated.

Digoxin - Drug Class

Cardiac Glycoside (inotrope)

Digoxin - MoA

↑ contractility (positive inotrope) and ↓ AV node conduction (negative chronotrope).

Digoxin - NC

Check apical pulse before administration. Continually assess for bradycardia; hold the dose and notify the provider if the heart rate is below established parameters, commonly less than 60 bpm in adults.

Monitor serum digoxin levels and electrolytes. The therapeutic range is typically 0.5 to 2.0 ng per mL; closely monitor potassium, magnesium, and calcium, as imbalances increase toxicity risk.

Evaluate for early signs of toxicity. Nausea, vomiting, visual disturbances such as halos or blurred vision, and confusion are early indicators and warrant prompt evaluation.

Adjust dose cautiously in renal impairment. Digoxin is primarily excreted by the kidneys; dose reduction and frequent monitoring are essential in patients with decreased renal function.

Digoxin - Critical Alerts

High Alert: Stop immediately if signs of digoxin toxicity appear. Toxicity can lead to life-threatening arrhythmias; notify the provider, hold further doses, and prepare for antidote administration such as digoxin immune Fab.

Amiodarone - Drug Class

Class III antiarrhythmic

Amiodarone - MoA

stabilizes arrhythmias (used for AFib, VT/VF).

Amiodarone - NC

Monitor ECG and thyroid, liver, and pulmonary function. Regularly assess for QT prolongation, thyroid imbalance, elevated liver enzymes, and signs of pulmonary toxicity during therapy.

Assess for visual disturbances and skin changes. Report symptoms such as blurred vision, corneal deposits, photosensitivity, or blue-gray skin discoloration, which may appear with long-term use.

Review medication interactions closely. Amiodarone has a long half-life and inhibits many CYP450 enzymes, increasing the effects and toxicity risks of several concurrent drugs, including digoxin and warfarin.

Use the loading dose with caution and monitor closely. Loading regimens are often necessary to achieve therapeutic levels quickly but require cardiac monitoring and frequent assessment.

Amiodarone - Critical Alerts

Stop if signs of pulmonary toxicity develop. Nonproductive cough, dyspnea, or pulmonary infiltrates require immediate evaluation and potential discontinuation to prevent irreversible lung damage.

Caution in thyroid dysfunction.
Amiodarone contains iodine and may cause either hypo- or hyperthyroidism; thyroid function must be monitored periodically throughout treatment

Adenosine - Drug Class

Antiarrhythmic

Adenosine - MoA

Slows AV node conduction dramatically, interrupting re-entrant SVT pathways to restore normal sinus rhythm.

Adenosine - NC

Administer as a rapid IV push with saline flush. Due to its ultra-short half-life, adenosine must be given quickly through a large-bore IV with immediate saline flush to confirm effectiveness.

Monitor ECG continuously during administration. A brief period of asystole or bradycardia is expected, and the therapeutic effect is confirmed before normal rhythm resumes.

Prepare the patient for transient symptoms. Educate patients that facial flushing, chest pressure, lightheadedness, or a sense of impending doom may occur but usually resolves within seconds.

Avoid in patients with AV block or sick sinus syndrome. Adenosine is contraindicated in those without a pacemaker due to its direct effect on AV node conduction

Adenosine - Critical Alerts

High Alert:
Use with caution in reactive airway disease. Adenosine can cause bronchospasm and is contraindicated in patients with severe asthma or chronic obstructive pulmonary disease.

Contraindicated in 2ⁿᵈ/3ʳᵈ degree heart block. Adenosine is contraindicated because it slows conduction through the AV node, which is already impaired in these blocks.

Atropine - Drug Class

Anticholinergic (muscarinic antagonist)

Atropine - MoA

Blocks acetylcholine at parasympathetic sites (e.g., SA & AV nodes), resulting in increased heart rate and decreased secretions.

Atropine - NC

Used as an antidote in cholinergic crisis (organophosphate poisoning). Atropine treats cholinergic crisis by blocking muscarinic receptors, reversing bradycardia and respiratory symptoms.

Assess heart rate and rhythm before and after dosing. Continuous ECG monitoring is essential to evaluate the therapeutic effect and detect arrhythmias.

Monitor for anticholinergic side effects.
Systemic cholinergic blockade may cause dry mouth, blurred vision, urinary retention, and constipation.

Educate on heat intolerance and hydration. Atropine can inhibit sweating and increase the risk of hyperthermia, especially in hot environments; advise adequate fluid intake.

Use cautiously in elderly patients. Older adults are more sensitive to CNS effects such as confusion, agitation, or hallucinations; monitor closely

Atropine - Critical Alerts

Caution:
Contraindicated in glaucoma. It may trigger acute angle-closure by increasing intraocular pressure.

Recognize the signs of anticholinergic toxicity. In overdose, atropine can produce a classic toxidrome including hyperthermia, dry mucosa, flushed skin, delirium, and mydriasis.

Have physostigmine available for severe overdose. This cholinesterase inhibitor is the antidote to reverse life-threatening central and peripheral anticholinergic effects

Epinephrine - Drug Class

Adrenergic agonist (catecholamine)

Epinephrine - MoA

Stimulates α1 (vasoconstriction → ↑BP), β1 (↑HR/contractility), and β2 (bronchodilation) receptors.

Epinephrine - NC

Use in cardiac arrest and anaphylaxis. Administer promptly in life-threatening conditions such as cardiac arrest, severe allergic reactions, or airway obstruction due to anaphylaxis.

Monitor for tachycardia and hypertension. Continuous monitoring is necessary during IV or IM administration due to potent cardiovascular effects, including increased myocardial oxygen demand.

Teach proper use of auto-injectors. Educate patients prescribed epinephrine for anaphylaxis on correct storage, injection technique, and the importance of seeking immediate medical care after use.

Evaluate for tremors and anxiety post-administration. CNS stimulation may cause nervousness, restlessness, or headache, typically resolved without intervention.

Infiltration requires immediate intervention. If extravasation occurs, promptly infiltrate the area with phentolamine to reverse local vasoconstriction and minimize tissue damage.

Epinephrine - Critical Alert

High Alert: Use caution in patients with cardiac disease. Epinephrine can precipitate arrhythmias, angina, or myocardial infarction; monitor closely in individuals with preexisting cardiovascular conditions.

Norepinephrine (Levophed) - Drug Class

Adrenergic agonist (vasopressor)

Norepinephrine - MoA

Primarily stimulates α1 receptors (intense vasoconstriction) and some β1 (↑heart contractility), leading to increased vascular resistance and BP.

Norepinephrine - NC

First-line vasopressor for septic shock. Norepinephrine causes vasoconstriction and elevation of blood pressure in shock and severe hypotension.

Titrate infusion based on hemodynamic response. Continuous blood pressure, heart rate, and urine output monitoring is needed to guide dose adjustments and assess organ perfusion.

Monitor extremities for signs of ischemia. Prolonged vasoconstriction may lessen blood flow to limbs and digits; assess for pallor, coldness, or mottling.

Support fluid resuscitation before vasopressor use. Check for adequate intravascular volume, as norepinephrine may be ineffective or harmful in hypovolemic states

Norepinephrine - Critical Alerts

High Alert: Infiltration can cause severe tissue necrosis. If extravasation occurs, administer phentolamine subcutaneously around the site to reverse local vasoconstriction

Dopamine - Drug Class

Adrenergic agonist/inotrope

Dopamine - MoA

Dose-dependent receptor effects: low→dopaminergic (renal perfusion), mid→β1 (↑HR/contractility), high→α1 (vasoconstriction).

Dopamine - NC

Monitor cardiac rhythm and hemodynamic parameters. Continuous ECG and vital signs monitoring are required to detect arrhythmias and guide titration based on blood pressure and urine output.

Verify for proper fluid volume before initiating therapy. Hypovolemia should be corrected before dopamine infusion to prevent ineffective perfusion and worsening hypotension.

Use central access when possible. Administer dopamine via a central line to reduce the risk of peripheral extravasation and tissue damage.

Adjust dosage gradually and observe for tachyarrhythmias. High doses may cause excessive vasoconstriction and increased cardiac workload; titrate slowly and assess for chest pain or palpitations

Dopamine - Critical Alerts

High Alert: Treat extravasation promptly with phentolamine. Peripheral infiltration may cause necrosis due to intense vasoconstriction and must be addressed immediately with antidote infiltration

Nitroglycerin - Drug Class

Nitrate (antianginal)

Nitroglycerin - MoA

venodilation (↓preload) and coronary artery dilation; at higher doses, also dilates arterioles (↓afterload)

Nitroglycerin - NC

Assess blood pressure before and during therapy. Monitor closely for hypotension, especially during IV infusion or when titrating transdermal or sublingual forms.

Evaluate for headache and flushing. Vasodilation often causes transient headache, dizziness, or facial flushing; reassure patients and adjust dose if needed.

Check nitrate-free intervals for tolerance prevention. For transdermal or oral long-acting forms, schedule drug-free periods daily to reduce the risk of nitrate tolerance.

Teach proper administration for angina relief. Instruct patients using sublingual tablets to sit or lie down during use, place under the tongue, and call emergency services if chest pain persists after one dose

Nitroglycerin - Critical Alert

High Alert:
Do not use with phosphodiesterase inhibitors. Concomitant use with drugs like sildenafil can cause severe hypotension and is contraindicated.

Watch for profound hypotension with rapid administration. Administer IV nitroglycerin slowly and titrate carefully; abrupt drops in blood pressure may compromise perfusion and lead to syncope or shock.

Atorvastatin - Drug Class

Statin (antihyperlipidemic)

Atorvastatin - MoA

Inhibits HMG-CoA reductase, the enzyme for cholesterol synthesis in liver – lowers LDL and total cholesterol; modestly raises HDL, lowers triglycerides.

Atorvastatin - NC

Monitor liver enzymes during therapy. Check AST and ALT at baseline and periodically, as hepatotoxicity may occur during statin use.

Assess for muscle pain and weakness. Myopathy and rhabdomyolysis are rare but serious adverse effects; report unexplained muscle symptoms promptly.

Reinforce adherence to timing and lifestyle changes. Take once daily, preferably in the evening, and emphasize the importance of diet and exercise in combination with medication.

Avoid grapefruit and excessive alcohol intake. Grapefruit inhibits CYP3A4 metabolism, increasing statin levels and toxicity risk; alcohol may exacerbate liver effects.

Atorvastatin - Critical Alerts

Caution: Discontinue if rhabdomyolysis is suspected. Signs include severe muscle pain, dark urine, and elevated creatine kinase; notify the physician and stop therapy immediately.

Furosemide - MoA

causes major diuresis (excretion of Na⁺, K⁺, Cl⁻, water).

Furosemide - NC

Monitor electrolytes and renal function. Frequent potassium, sodium, magnesium, and creatinine assessment is important to prevent electrolyte imbalances and nephrotoxicity.

Assess for signs of volume depletion. Monitor for hypotension, dizziness, dry mucous membranes, and decreased urine output, particularly in high doses or elderly patients.

Administer early in the day. Give in the morning to minimize nocturia and improve adherence to therapy.

Evaluate for hearing changes during IV use. High-dose or rapid IV administration may cause ototoxicity; assess for tinnitus or hearing loss and infuse slowly.

Encourage potassium-rich foods or supplements. Hypokalemia is a common side effect and may require dietary counseling or potassium replacement

Furosemide - Critical Alerts

Caution: Watch for severe hypokalemia or dehydration. Life-threatening arrhythmias and acute kidney injury can result from excessive diuresis or electrolyte loss; intervene promptly and notify the physician

Spironolactone - Drug Class

Potassium-sparing diuretic

Spironolactone - MoA

causes excretion of Na⁺/water and retention of K⁺.

Spironolactone - NC

Monitor serum potassium and renal function. Regularly assess for hyperkalemia and rising creatinine, particularly in patients with impaired renal function or those on ACE inhibitors or ARBs.

Assess for endocrine-related side effects. Due to its anti-androgenic effects, gynecomastia, menstrual irregularities, and impotence may occur.

Teach dietary precautions with potassium intake. Advise patients to avoid potassium-rich foods and salt substitutes to reduce the risk of hyperkalemia.

Administer consistently with or without food. Reinforce adherence to the dosing schedule and educate on signs of electrolyte imbalance, such as muscle weakness or palpitations.

Spironolactone - Critical Alert

Caution: Discontinue if life-threatening hyperkalemia develops. Immediate intervention is required if potassium exceeds safe limits or if ECG changes indicate cardiac instability

Hydrochlorothiazide - Drug Class

Thiazide diuretic

Hydrochlorothiazide - MoA

Inhibits NaCl reabsorption in the distal convoluted tubule, promoting moderate diuresis and reducing blood volume/BP.

Hydrochlorothiazide - NC

Monitor electrolytes and glucose levels. Regularly assess for hypokalemia, hyponatremia, and elevated blood glucose, especially in patients with diabetes or on digoxin.

Check blood pressure and signs of dehydration. Evaluate for orthostatic hypotension, dizziness, and dry mucous membranes, which may indicate excessive fluid loss.

Administer in the morning to prevent nocturia. Giving the dose early helps maintain adherence while decreasing the risk of sleep disturbance due to frequent urination.

Encourage potassium-rich foods. Dietary potassium may help counteract potassium loss and reduce the risk of muscle cramps or arrhythmias

Hydrochlorothiazide - Critical Alerts

Caution:
Use caution in patients with sulfa allergy. Hydrochlorothiazide may trigger hypersensitivity reactions in individuals with known sulfonamide allergies.

Discontinue if severe electrolyte imbalance occurs. Life-threatening complications can arise from profound hypokalemia or hyponatremia and require prompt correction.

Epoetin Alpha - Drug Class

Erythropoiesis-stimulant

Epoetin Alpha - MoA

Synthetic erythropoietin hormone that stimulates RBC production in bone marrow.

Epoetin Alpha - NC

Monitor hemoglobin and hematocrit regularly. Titrate dose based on response and avoid exceeding target hemoglobin levels to reduce cardiovascular risk.

Assess for hypertension during therapy. Epoetin alfa may elevate blood pressure, particularly in patients with chronic kidney disease; monitor closely and manage accordingly.

Evaluate for signs of thromboembolic events. Increased hematocrit may raise the risk of clotting, especially in patients with cancer or a history of vascular disease.

Administer via subcutaneous or IV route. Follow the institution protocol for route and dosing schedule; do not shake the vial as it may denature the protein.

Epoetin Alpha - Critical Alerts

Black Box: Hold if hemoglobin rises too rapidly or exceeds 11 g per dL. Rapid correction can increase the risk of stroke, myocardial infarction, and death, particularly in patients with renal failure.

Ferrous Sulfate - Drug Class

Iron Supplement (Hematopoietic Agent)

Ferrous Sulfate - NC

Administer on an empty stomach for best absorption. Give 1 hour before or 2 hours after meals, but may give with food to minimize gastrointestinal upset if necessary.

Monitor for gastrointestinal side effects. Nausea, constipation, and dark stools are common and may affect adherence; encourage hydration and fiber intake.

Avoid coadministration with calcium, antacids, or certain antibiotics. These can impair iron absorption; space dosing appropriately to enhance efficacy.

Reinforce proper administration technique. Advise patients to take tablets with a full glass of water and avoid crushing or chewing extended-release forms.

Ferrous Sulfate - Critical Alerts

High warning:

Iron overdose is potentially fatal in children. Store ferrous sulfate out of reach and educate caregivers on the importance of proper storage and immediate intervention if accidental ingestion occurs.

Monitor for signs of iron overload with long-term use. Excessive supplementation may lead to hemosiderosis; assess ferritin and transferrin saturation in patients on chronic therapy

Rivaroxaban - Drug Class

Factor Xa Inhibitor / Anticoagulant (Hematologic Agent)

Rivaroxaban - MoA

it significantly reduces thrombin generation, thereby decreasing the likelihood of clot formation. It is commonly used for preventing deep vein thrombosis (DVT), pulmonary embolism (PE), and managing thromboembolic risks in patients with atrial fibrillation

Rivaroxaban - NC

Monitor for signs of bleeding. Assess for bruising, hematuria, melena, or prolonged bleeding; educate patients to report any unusual bleeding immediately.

Avoid abrupt discontinuation. Sudden stoppage increases the risk of thromboembolic events; taper only under provider guidance or when switching to another anticoagulant.

Use cautiously with other anticoagulants or antiplatelets. Concomitant use increases bleeding risk; review all medications for interactions.

Renal function affects dosing. Adjust dose in renal impairment and monitor kidney function regularly in elderly or high-risk populations

Rivaroxaban - Critical Alerts

Patients must avoid abrupt cessation without provider consultation. Premature discontinuation of rivaroxaban significantly increases the risk of thrombotic events, including stroke and myocardial infarction. Currently, there is no specific reversal agent; thus, extreme caution in dosing and monitoring is critical.

Warfarin - Drug Class

Vitamin K antagonist (oral anticoagulant)

Warfarin - MoA

Inhibits vitamin K-dependent clotting factor synthesis (factors II, VII, IX, X) in the liver.

Warfarin - NC

Monitor INR regularly to guide dosing. Maintain INR within the target range (typically 2 to 3) to balance the risk of bleeding and clotting.

Assess for signs of bleeding and educate on precautions. Watch for bruising, gum bleeding, hematuria, and melena; instruct patients to use soft toothbrushes and avoid activities that increase injury risk.

Maintain consistent dietary vitamin K intake. Sudden increases or decreases in vitamin K from green leafy vegetables can alter drug effectiveness.

Review for drug and herbal interactions. Many medications and supplements, including antibiotics and NSAIDs, can increase bleeding risk or alter INR

Warfarin - Critical Alerts

Black Box: Discontinue immediately in the presence of signs of serious bleeding or INR above the therapeutic range. Reverse anticoagulation with vitamin K or prothrombin complex concentrate as clinically indicated.

High Alert: Contraindicated in pregnancy. Warfarin crosses the placenta and can cause fetal bleeding and malformations; use an alternative anticoagulant during pregnancy.

heparin - drug class

anticoagulant

Heparin - MoA

Activates antithrombin III, which inactivates thrombin and factor Xa, thereby preventing fibrin formation.

Heparin - NC

Monitor aPTT to maintain the therapeutic range. Adjust dose based on activated partial thromboplastin time and institutional protocols to confirm adequate anticoagulation without excessive bleeding.

Assess for signs of bleeding. Monitor for hematuria, melena, hematomas, or oozing at IV sites, and instruct patients to report unusual bruising or bleeding.

Use cautiously with invasive procedures. Temporarily discontinue before surgery or procedures that carry bleeding risk; restart as directed based on risk assessment.

Rotate subcutaneous injection sites. For prophylactic dosing, administer in the abdomen away from scars or bruises, and avoid massaging to prevent hematoma formation.

Heparin - Critical Alerts

High Alert:
Monitor for heparin-induced thrombocytopenia. Abrupt platelet drop may indicate HIT, a severe immune-mediated reaction; discontinue heparin and initiate alternative anticoagulation if suspected.

Have protamine sulfate available for overdose. Protamine is the reversal agent for heparin and should be administered immediately in cases of severe bleeding or overdose.

Enoxaparin - Drug Class

LMWH (low molecular weight heparin)

Enoxaparin - MoA

Enhances antithrombin activity to inactivate factor Xa (more selective action than heparin).

Enoxaparin - NC

Administer via deep subcutaneous injection. Alternate injection sites and avoid massaging to prevent local irritation or hematoma formation.

Monitor for signs of bleeding. Assess for bruising, hematuria, and GI bleeding and notify the physician if any bleeding occurs, especially in patients with renal impairment or on other anticoagulants.

Evaluate platelet counts during therapy. Enoxaparin may rarely cause heparin-induced thrombocytopenia; monitor CBC and discontinue if the platelet count drops significantly.

Educate on self-administration and timing. Instruct patients on proper injection technique and importance of consistent timing for dosing.

Adjust the dose for renal impairment. Decreased clearance in patients with reduced renal function increases bleeding risk; modify the dose accordingly.

Enoxaparin - Critical Alerts

High Alert: Do not use interchangeably with unfractionated heparin. Enoxaparin has a different pharmacokinetic profile and dosing regimen and should not be substituted without proper evaluation.

Avoid use in patients undergoing spinal or epidural procedures. Concurrent anticoagulation increases the risk of spinal hematoma, which may lead to paralysis; follow strict timing guidelines.

Antidote: Protamine partially reverses effect if needed.

Clopidogrel - Drug Class

Antiplatelet

Clopidogrel - MoA

reduced platelet aggregation

Clopidogrel - NC

Monitor for signs of bleeding. Observe for bruising, epistaxis, hematuria, or gastrointestinal bleeding, especially in patients receiving anticoagulants or NSAIDs.

Assess baseline platelet function and CBC. Regular monitoring helps detect thrombocytopenia or potential bone marrow suppression during prolonged use.

Educate on avoiding injury and OTC medications. Advise patients to use caution with razors and contact sports and to consult providers before using aspirin or NSAIDs.

Discontinue before surgery if advised. Clopidogrel increases surgical bleeding risk and should be held per provider guidance, typically 5 to 7 days preoperatively.

Clopidogrel - Critical Alerts

Caution: Do not use in active bleeding or peptic ulcer disease. Clopidogrel is contraindicated in patients at high risk for hemorrhage.

Do not use in active bleeding or peptic ulcer disease. Clopidogrel is contraindicated in patients at high risk for hemorrhage.

Watch for thrombotic thrombocytopenic purpura. Report any signs of neurologic changes, fever, renal dysfunction, or unexplained bruising, as TTP is a rare but life-threatening complication.

Aspirin - Drug Class

NSAID / Antiplatelet (salicylate)